Report Library
All Reports
Inpatient Infections Pulse
October 08, 2014
BioMedTracker will be offering KOL Reports and Physician Pulse Surveys through 2014 for purchase a la carte, or access to all reports
and surveys can be purchased as a subscription to KOL Insight. For more information on KOL Insight subscription, please email BioMedTracker or call
BioMedTracker
Client Services at (858) 200-2357.
We conducted a survey of 20 infectious diseases specialists to evaluate current drug usage for the treatment of selected severe/inpatient infections and gauge physician interest in new drugs.
Drug candidates discussed: Cubicin (daptomycin), Dalvance (dalbavancin), Orbactiv (oritavancin), Zyvox (linezolid), vancomycin, metronidazole, Dificid (fidaxomicin), Xifaxan (rifaximin); beta-lactam–beta-lactamase inhibitor combination drugs.
To purchase the Inpatient Antibiotics Survey, click the link at the top of the page.
For our disclosures, please read the BioMedTracker Research Standards.
We conducted a survey of 20 infectious diseases specialists to evaluate current drug usage for the treatment of selected severe/inpatient infections and gauge physician interest in new drugs.
Drug candidates discussed: Cubicin (daptomycin), Dalvance (dalbavancin), Orbactiv (oritavancin), Zyvox (linezolid), vancomycin, metronidazole, Dificid (fidaxomicin), Xifaxan (rifaximin); beta-lactam–beta-lactamase inhibitor combination drugs.
To purchase the Inpatient Antibiotics Survey, click the link at the top of the page.
For our disclosures, please read the BioMedTracker Research Standards.
| Disease Group Covered: | Infectious Disease |
Additional Resources: